Clinical Trials Directory

Trials / Completed

CompletedNCT00458289

Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lanthanum Carbonate

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
12 (actual)
Sponsor
University of Illinois at Chicago · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Patients with end-stage renal disease (ESRD) commonly have high concentrations of phosphorous, a mineral, in the blood (hyperphosphatemia). This is a result of their inability to excrete phosphorous by the kidneys. This in turn may result in the development of a condition known as secondary hyperparathyroidism and renal osteodystrophy or bone disease. As such, these patients often receive medications known as phosphate binders such as calcium carbonate or acetate, sevelamer, aluminum hydroxide and lanthanum carbonate to manage and treat hyperphosphatemia. Lanthanum carbonate is a newly available phosphate binding agent that is effective in the management of hyperphosphatemia and preventing secondary hyperparathyroidism. It works in the gastrointestinal tract by binding to the phosphorus in the diet. ESRD patients taking lanthanum carbonate are counseled to chew the tablets completely before swallowing, with or immediately after meals. However, patients who are intubated or receiving nutrition via feeding tubes are unable to chew the tablets. For these patients, medications are commonly crushed and administered via the tube. Moreover, some patients prefer to crush the tablets and mix it with food instead of chewing. To date, it is not known if crushing the lanthanum carbonate tablets prior to administration and taking it with food would be as effective as chewing them. The purpose of this study is to compare the efficacy of phosphate binding between chewed and crushed lanthanum carbonate tablets.

Conditions

Interventions

TypeNameDescription
DRUGLanthanum carbonate (chewed vs. crushed)single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder

Timeline

Start date
2007-01-01
Primary completion
2008-06-01
Completion
2008-08-01
First posted
2007-04-10
Last updated
2019-12-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00458289. Inclusion in this directory is not an endorsement.